Status:
COMPLETED
Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes
Lead Sponsor:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine in type 2 diabetic patients in secondary failure to combined oral therapy whether, besides improvement in glycemic control, addition of exenatide, a new drug ...
Eligibility Criteria
Inclusion
- type 2 diabetes subjects
- 40 to 80 years
- body mass index (BMI) between 25 and 40 kg/m²
- baseline glycated haemoglobin (HbA1c) \> 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin
Exclusion
- previous or current use of glitazone
- previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
- previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00948168
Start Date
July 1 2008
End Date
July 1 2009
Last Update
July 31 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cliniques universitaires St-Luc
Brussels, Brabant, Belgium, 1200